Recent advances in antiplatelet therapy

Australian Prescriber

Volumn 19, Issue 4, 1996, Pages 98-101

  Lefkovits, Jeffrey ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; DIPYRIDAMOLE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; LAMIFIBAN; RIDOGREL; SULFINPYRAZONE; TICLOPIDINE; TIROFIBAN; XEMILOFIBAN;

ARACHIDONIC ACID METABOLISM; BLOOD CLOT LYSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DILATATION; DIARRHEA; DRUG EFFICACY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; NEUTROPENIA; RASH; SECONDARY PREVENTION; SHORT SURVEY; STROKE; THROMBOCYTE AGGREGATION; UNSTABLE ANGINA PECTORIS;

EID: 0029850310     PISSN: 03128008     EISSN: None     Source Type: Journal    
DOI: 10.18773/austprescr.1996.091     Document Type: Short Survey

References (13)

1. The EPIC Investigation. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty [see comments]. N Engl J Med 1994;330:956-61.
2. Comment in: N Engl J Med 1994;330:1006-7.
3. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators [see comments]. Lancet 1994;343:881-6.
4. Comment in: Lancet 1994;343:1434-5.
5. Tcheng JE, Lincoff AM, Sigmon KN, Kitt MM, Califf RM, Topol EJ. Platelet glycopotein IIb/IIIa inhibition with Integrelin during percutaneous coronary intervention: The IMPACT II trial. Circulation 1995;92(8 Suppl):1543.
6. Colombo A, Hall P, Nakamura S, Almagor Y, Maiello L, Martini G, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance [see comments]. Circulation 1995;91:1676-88.
7. Comment in: Circulation 1995;91:1891-3.
8. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-60.
9. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-9.
10. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke [see comments]. Lancet 1989;1:1215-20.
11. Comment in: Lancet 1989;2:442-3.
12. Hass WK, Easton JD, Adams HP Jr, Pryse-Phillips W, Molony BA, Anderson S, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group [see comments]. N Engl J Med 1989;321:501-7.
13. Comment in: N Engl J Med 1990;322:404-5.